Added to YB: 2025-12-02
Pitch date: 2025-11-28
LXEO [bullish]
Lexeo Therapeutics, Inc.
+1.24%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.
Market Cap
$719.7M
Pitch Price
$9.65
Price Target
16.73 (+71%)
Dividend
N/A
EV/EBITDA
-5.49
P/E
-4.02
EV/Sales
N/A
Sector
Biotechnology
Category
growth
The Most Overlooked Biotech in Rare Disease Medicine - Lexeo Therapeutics, Inc.
LXEO: Gene therapy for Friedreich's ataxia cardiomyopathy shows 23% improvement in left ventricular mass index at 12mo (n=6), exceeding FDA 10% threshold. Lead to registrational study 1H 2026. $276M cash extends runway to 2028. Risk-weighted target $16.73 vs $9.63 (+74% upside).
Read full article (6 min)